Q-omics provides the consensus-scored GFRA3 profile across patient tissues and cancer cell-line models. GFRA3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GFRA3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GFRA3 RNA expression shows 14,971 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where GFRA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GFRA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GFRA3 survival associations across molecular data types. GFRA3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GFRA3 RNA expression–survival associations across cancer types. High GFRA3 expression shows unfavorable associations in ACC, LIHC, MESO and LGG, but favorable associations in LUAD and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GFRA3 RNA expression.
This table summarizes GFRA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GFRA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GFRA3 shows lower tumor expression in KIRC, BLCA, COAD, KICH, THCA and KIRP. The KIRC box plot shows higher GFRA3 RNA expression in normal versus tumor tissue (log2 FC = −0.478, t-test p < 0.001).
This table shows molecular features associated with GFRA3 in patient tissues and cancer cell lines. In patient samples, GFRA3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GFRA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
